Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials

By afschroeder • November 29, 2025

Guttman-Yassky E, Kabashima K, Worm M, Luna PC, Hong HC, Chovatiya R, Bernstein JA, Kern JS, Ehst BD, Magnolo N, Herranz-Pinto P, Stein Gold L, Sofen H, Pink AE, Esfandiari E, Arai T, Yang Y, Shi R, Barragan C, Kricorian G, Schwartz-Sagi L, Bissonnette R. Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials. Lancet. 2025 Nov 25:S0140-6736(25)01865-3. doi: 10.1016/S0140-6736(25)01865-3. Epub ahead of print. PMID: 41314226.

Tags: Dermatology, Olive View DoM, Publications

A scalp to make you squirm: Cutaneous myiasis hiding a unique presentation of disseminated coccidioidomycosis

Duldulao JM, Modanlo N, Boppana S, Adachi K, Dong HV, Kaur I, Nielsen-Saines K, Terrell J, Cheng CE, Malhotra S. A scalp to make you[...]

Is Cumulative Life Course Impairment Considered in Psoriasis Management? A Multinational Survey of People with Psoriasis and Healthcare Professionals

Matthews R, Armstrong AW, Augustin M, Baker C, Carrascosa JM, Kirby B, Langley R, McBride S, Reich A, Romiti R, Sampogna F, Warren RB. Is[...]

T cell-macrophage interactions in tuberculosis: What we’ve got here is failure to communicate

Mortensen R, Arlehamn CSL, Coler RN, Gerner MY, Goletti D, Lewinsohn DA, Modlin RL, Musvosvi M, Rengarajan J, Urdahl KB, Walzl G, Behar SM, Barber[...]